Search | Clinical Trials Finder

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: ORP-101, Placebo; Drug
Lead sponsor: OrphoMed, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 321 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 74
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions: Rifaximin, Glucose and lactulose hydrogen breath testing; Drug · Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diarrhea-Predominant Irritable Bowel Syndrome
Interventions: Glutamine; Drug
Lead sponsor: Tulane University; Other
Eligibility: 18 Years to 72 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Gluten free diet, Gluten rich diet; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: ONO-2952, ONO-2952 Matching Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 48
States / cities: Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, BMS-562086; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome
Interventions: 250 mg LX1033 tablets, Placebo tablet; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 81
States / cities: Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more

Conditions: Irritable Bowel Syndrome
Interventions: Olorinab, Placebo; Drug
Lead sponsor: Arena Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 69
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more

Conditions: Irritable Bowel Syndrome, Diarrhea
Interventions: Donor Fecal Microbiota Transplantation, Autologous Fecal Microbiota Transplantation; Biological
Lead sponsor: Madhusudan (Madhu) Grover, MBBS; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 257
States / cities: Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Asimadoline, Placebo; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 142
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: DNK333, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 180 participants
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Irritable Colon, Irritable Bowel Syndrome (IBS)
Interventions: Alosetron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 177
States / cities: Birmingham, Alabama • Calera, Alabama • Tuscaloosa, Alabama + 149 more

Conditions: Irritable Bowel Syndrome
Interventions: 25mg Eluxadoline, 100mg Eluxadoline; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2032
U.S. locations: 6
States / cities: Corona, California • Miami, Florida • Stockbridge, Georgia + 2 more

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome
Interventions: EnteraGam; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 288
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more

Conditions: Non-Constipation Irritable Bowel Syndrome
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 88
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more

Conditions: Irritable Bowel Syndrome
Interventions: 0.075 mg RVX-100, 0.125 mg RVX-100, 0.250 mg RVX-100, placebo; Drug
Lead sponsor: Revogenex, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 232
States / cities: Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: open-label rifaximin, double-blind placebo, double-blind rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 293
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 226 more

Conditions: Diarrhea-predominant Irritable Bowel Syndrome
Interventions: BOS-589, Placebo; Drug
Lead sponsor: Boston Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 58
States / cities: Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 48 more

Conditions: Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions: Antihistamine, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pain
Interventions: Probiotics - Lactobacillus and bifidobacterium, Placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Search by objective public record fields.

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

Glutamine for the Treatment of Patients With Irritable Bowel Syndrome

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Fecal Microbiota Transplantation for IBS

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Retrospective Study of IBS-D Patients Previously Receiving SBI

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study

Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

Efficacy of Probiotic Bacteria in Subjects With IBS or Functional Diarrhea/ Bloating